Abbott Laboratories trades at decade low with growth and dividend streak, poised for EPS boost by 2028-29.

Abbott Laboratories is currently valued at a decade low of 17.7 times forward earnings despite strong 13.2% growth in its Medical Devices segment in Q1 2026 and a 54-year dividend streak. Key growth drivers include synergies with Exact Sciences, expansion of CMS continuous glucose monitoring (CGM) reimbursement, and recovery in Nutrition segment margins, which could add $1.27 to $1.73 in earnings per share by 2028-2029. The market underestimates Abbott's commercial leverage and potential upside from distribution synergies and CMS reimbursement expansion, leading to a buy rating with a 12-month target price of $126 and intrinsic value above $150 over multiple years, supported by strong cash flow and dividend growth.